PET/CT显像在肝细胞肝癌诊断中的研究进展

王振光; 王洋洋; 王振光; 王洋洋

doi:10.3760/cma.j.issn.1673-4114.2015.02.016

[1]

Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2):74 -108. doi: 10.3322/canjclin.55.2.74

[2]

Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90. doi: 10.3322/caac.20107

[3]

方京龙, 刘淑玲, 张广明.肝硬化和肝癌MRI诊断研究进展[J].国际放射医学核医学杂志, 2014, 38(3):207-211. doi: 10.3760/cma.j.issn.1673-4114.2014.03.015

[4]

Murakami T, Kim T, Takamura M, et al. Hypervascular hepatocell-ular carcinoma:detection with double arterial phase multi-detector row helical CT[J]. Radiology, 2001, 218(3):763-767.

[5]

Liu S, Wah Chan K, Tong J, et al. PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma:a case report and a summary of recent literature[J]. QJM, 2011, 104(6):477-483. doi: 10.1093/qjmed/hcr040

[6]

Sharma B, Martin A, Zerizer I. Positron emission tomography-computed tomography in liver imaging[J]. Semin Ultrasound CT MR, 2013, 34(1):66-80. doi: 10.1053/j.sult.2012.11.006

[7]

Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors[J]. J Cancer Res Clin Oncol, 2004, 130(5):266-272. doi: 10.1007/s00432-003-0527-6

[8]

Chen YK, Hsieh DS, Liao CS, et al. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence[J]. Anticancer Res, 2005, 25(6C):4719-4725.

[9]

Park JW, Kim JH, Kim SK, et al. A prospective evaluation of ¹⁸F-FDG and ¹¹C-acetate PET/CT for detection of primary and metasta-tic hepatocellular carcinoma[J]. J Nucl Med, 2008, 49(12):1912-1921. doi: 10.2967/jnumed.108.055087

[10]

Wolfort RM, Papillion PW, Turnage RH, et al. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level and histologic grade[J]. Int Surg, 2010, 95(1):67-75.

[11]

Talbot JN, Gutman F, Fartoux L, et al. PET/CT in patients with hepatocellular carcinoma using[¹⁸F] fluorocholine:preliminary comparison with[¹⁸F] FDG PET/CT[J]. Eur J Nucl Med Mol Ima-ging, 2006, 33(11):1285-1289.

[12]

Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma[J]. Clin cancer Res, 2007, 13(2 Pt 1):427-433.

[13]

Seo S, Hatano E, Higashi T, et al. P-glycoprotein expression affects [¹⁸F] fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro[J]. Int J Oncol, 2009, 34(5):1303-1312.

[14]

吴冰, 韩磊, 姜磊, 等. ¹⁸F-FDG PET/CT双时相显像在肝细胞肝癌诊断中的应用价值[J].中华核医学与分子影像杂志, 2014, 34(1):58-59. doi: 10.3760/cma.j.issn.2095-2848.2014.01.017

[15]

Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation:acetate metabolism in tumor cells[J]. Nucl Med Biol, 2001, 28(2):117-122.

[16]

Salem N, Kuang Y, Corn D, et al. [(Methyl)1-¹¹C]-acetate metabolism in hepatocellular carcinoma[J]. Mol Imaging Biol, 2011, 13(1):140-151.

[17]

Yun M, Bang SH, Kim JW, et al. The importance of acetyl coenzyme A synthetase for ¹¹C-acetate uptake and cell survival in hepatocellular carcinoma[J]. J Nucl Med, 2009, 50(8):1222-1228.

[18]

Kuang Y, Salem N, Wang F, et al. A colorimetric assay method to measure acetyl-CoA synthetase activity:application to woodchuck model of hepatitis virus-induced hepatocellular carcinoma[J]. J Biochem Biophys Methods, 2007, 70(4):649-655. doi: 10.1016/j.jbbm.2007.02.008

[19]

Ho CL, Yu SC, Yeung DW. ¹¹C-acetate PET imaging in hepatocell-ular carcinoma and other liver masses[J]. J Nucl Med, 2003, 44(2):213-221.

[20]

Hwang KH, Choi DJ, Lee SY, et al. Evaluation of patients with hepa-tocellular carcinomas using [¹¹C]acetate and [¹⁸F] FDG PET/CT:A preliminary study[J]. Appl Radiat Isot, 2009, 67(7-8):1195-1198. doi: 10.1016/j.apradiso.2009.02.011

[21]

Ponde DE, Dence CS, Oyama N, et al. ¹⁸F-fluoroacetate:a potential acetate analog for prostate tumor imaging—in vivo evaluation of ¹⁸F-fluoroacetate versus ¹¹C-acetate[J]. J Nucl Med, 2007, 48(3):420-428.

[22]

Takemoto K, Hatano E, Nishii R, et al. Assessment of [¹⁸F]-fluoroacetate PET/CT as a tumor-imaging modality:preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor[J]. Ann Nucl Med, 2014, 28(4):371-380.

[23]

Lindhe O, Sun A, Ulin J, et al. [¹⁸F] Fluoroacetate is not a functional analogue of [¹¹C] acetate in normal physiology[J]. Eur J Nucl Med Mol Imaging, 2009, 36(9):1453-1459. doi: 10.1007/s00259-009-1128-7

[24]

Ho CL, Cheung MK, Chen S, et al. ¹⁸F-fluoroacetate positron emi-ssion tomography for hepatocellular carcinoma and metastases:an alternative tracer for ¹¹C-acetate?[J]. Mol Imaging, 2012, 11(3):229-239.

[25]

Tenley N, Corn DJ, Yuan L, et al. The effect of fasting on PET Imaging of Hepatocellular Carcinoma[J]. J Cancer Ther, 2013, 4(2):561-567.

[26]

Torizuka T, Kanno T, Futatsubashi M, et al. Imaging of gynecologic tumors:comparison of ¹¹C-choline PET with ¹⁸F-FDG PET[J]. J Nucl Med, 2003, 44(7):1051-1056.

[27]

Salem N, Kuang Y, Wang F, et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[¹⁸F] fluoro-D-glucose, 6-deoxy-6[¹⁸F] fluoro-D-glucose, [1-¹¹C]-acetate and[N-methyl-¹¹C]-choline[J]. Q J Nucl Med Mol Imaging, 2009, 53(2):144-156.

[28]

Kuang Y, Salem N, Tian H, et al. Imaging lipid synthesis in hepatocellular carcinoma with[methyl-¹¹c]choline:correlation with in vivo metabolic studies[J]. J Nucl Med, 2011, 52(1):98-106.

[29]

Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detection of hepatocellular carcinoma using ¹¹C-choline PET:comparison with ¹⁸F-FDG PET[J]. J Nucl Med, 2008, 49(8):1245-1248. doi: 10.2967/jnumed.108.052639

[30]

Balogova S, Bumsel F, Kerrou K, et al. La fluorocholine (¹⁸F) a une utilité clinique dans le cancer de la prostate et le carcinome hépatocellulaire… parfois chez le même malade[J]. Médecine Nucléaire, 2010, 34(7):378-382. doi: 10.1016/j.mednuc.2010.05.007

[31]

Liu Q, Peng ZM, Liu QW, et al. The role of ¹¹C-choline positron emission tomography-computed tomography and videomedi-astinoscopy in the evaluation of diseases of middle mediastinum[J]. Chin Med J(Engl), 2006, 119(8):634-639.

[32]

Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer[J]. Eur Urol, 2011, 59(1):51-60.

[33]

Yamamoto Y, Nishiyama Y, Ishikawa S, et al. Correlation of ¹⁸FLT and ¹⁸FDG uptake on PET with Ki-67 immunohistochemistry in non small lung cancer[J]. Eur J Nucl Med Mol Imaging, 2007, 34(10):1610-1616. doi: 10.1007/s00259-007-0449-7

[34]

Eckel F, Herrmann K, Schmidt S, et al. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker ¹⁸F-fluorothymidine[J]. J Nucl Med, 2009, 50(9):1441-1447.